☆ 4.2 Article

Treatment sequences and drug costs from diagnosis to death in multiple myeloma

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma

Kandice A. A. Kapinos et al.

Summary: This study compares the expected costs and quality-adjusted life years (QALYs) gained among three BCMA-directed therapies in triple refractory MM patients. The results show that the total cost of CAR-T therapy is six times higher than belamaf, but the QALYs gained are 6 to 8 times higher. The study suggests that CAR-T therapy is approaching standard ICER thresholds.

CANCER CONTROL (2023)

Add to Collection

Review Oncology

Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review

Rafael Fonseca et al.

Summary: This systematic literature review aimed to understand the impact of disease progression, line of therapy, and clinical response on health-related quality of life in multiple myeloma patients. Through multiple rounds of screening, 41 studies were included, indicating that disease progression and increasing lines of therapy were associated with worsened patient HRQoL, while increasing depth of response was associated with improved patient HRQoL.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Letter Hematology

High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study

Christine Bennink et al.

HEMASPHERE (2023)

Add to Collection

Article Oncology

Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States

Sundar Jagannath et al.

Summary: In this retrospective US claims-database study, patients with MM who received >= 4 prior LOTs, including triple-class exposure (TCE), continued to experience high healthcare costs that were mostly attributable to anti-myeloma drugs and their administration.

ONCOLOGY AND THERAPY (2022)

Add to Collection

Article Medicine, General & Internal

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody

Ajai Chari et al.

Summary: Talquetamab treatment exhibited common adverse events like cytokine release syndrome, skin-related events, and dysgeusia, which were primarily low-grade; however, the drug induced substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Hematology

Quality of end-of-life care in multiple myeloma: A 13-year analysis of a population-based cohort in Ontario, Canada

Ghulam Rehman Mohyuddin et al.

Summary: Optimizing end-of-life care for multiple myeloma is still needed. A study in Ontario, Canada analyzed an administrative cohort between 2006 and 2018, finding that many patients still receive aggressive care at the end of life, but the adoption of supportive care has increased. Age, income, and community size were identified as factors influencing the receipt of supportive care.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Zoe McQuilten et al.

Summary: This study investigated the frequency and causes of early mortality in patients with newly diagnosed multiple myeloma. An analysis of patient registry data from Australia and New Zealand revealed that 9.1% of patients died within 12 months of diagnosis, with 4.5% of deaths occurring within 6 months. Age, performance status, serum albumin, cardiac disease, and International Staging System were identified as independent predictors of early mortality.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Economics

Beyond medicines' barriers: exploring the true cost of multiple myeloma

Mimi Choon-Quinones et al.

Summary: The study aimed to quantify and evaluate all costs associated with multiple myeloma (MM) from a healthcare and societal perspective, emphasizing certain underestimated costs. The results revealed that with combination treatments, drug costs have become the most significant component of total healthcare costs. Optimizing treatment pathways not only prolongs patient survival and maintains quality of life, but also has the potential to generate cost savings for all stakeholders.

JOURNAL OF MEDICAL ECONOMICS (2022)

Add to Collection

Article Medicine, General & Internal

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau et al.

Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019

Stacie B. Dusetzina et al.

Summary: Prescription drug spending has become a topic of increased interest, and this study aimed to estimate the proportion of healthcare spending contributed by prescription drugs and assess the spending on retail and clinician-administered prescriptions. The research found that, even after accounting for postsale rebates, approximately 27% of total spending among fee-for-service Medicare beneficiaries enrolled in Part D was spent on prescription drugs in 2019.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Hematology

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

Nico Gagelmann et al.

Lancet Haematology (2022)

Add to Collection

Article Oncology

Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany

Monika Engelhardt et al.

Summary: This study reveals that patients with multiple myeloma have impaired health-related quality of life (HRQoL) which deteriorates with increasing lines of therapy. Eastern Cooperative Oncology Group performance status is the strongest determinant of HRQoL.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Article Oncology

Trends in the multiple myeloma treatment landscape and survival: a US analysis using 2011-2019 oncology clinic electronic health record data

Megan Braunlin et al.

Summary: The treatment landscape for multiple myeloma has significantly evolved over the past decade, with an increase in the use of new drugs and a trend towards using triplet therapy combinations. As the line of therapy increases, patients' overall survival decreases, and patients diagnosed more recently have a longer survival time.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Economics

Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness

Manuel Neves et al.

Summary: This study assesses the burden and cost of Multiple Myeloma in Portugal from the perspective of the National Health Service. The results show that the burden of MM is mainly attributed to years of life lost due to premature deaths. The average yearly direct cost per MM patient is 31,449 euros.

PHARMACOECONOMICS (2021)

Add to Collection

Article Oncology

Hospitalization at the end of life in patients with multiple myeloma

Saqib Abbasi et al.

Summary: This study shows that patients with multiple myeloma who die in the hospital often require blood transfusions and have a high infection burden. Palliative care and hospice involvement has increased over time but remains low, and inpatient mortality has decreased but MM patients still die in the hospital at a higher rate than the general population.

BMC CANCER (2021)

Add to Collection

Review Oncology

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma

Maarten R. Seefat et al.

Summary: New treatments for multiple myeloma can improve survival but come with higher costs, with cost-effectiveness ratios generally exceeding current willingness-to-pay thresholds. Access to promising treatments may require improved cost-effectiveness or acceptance of higher cost-effectiveness ratios.

CANCERS (2021)

Add to Collection

Article Medicine, General & Internal

Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US

Kaustuv Bhattacharya et al.

Summary: The study found significant burden on Medicare associated with diagnosis and care among older adults with MM, with costs and drivers varying across different phases of the cancer care continuum.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Oncology

Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France

Nicolas Despiegel et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)

Add to Collection

Article Public, Environmental & Occupational Health

Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy

C. L. Bekker et al.

RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY (2019)

Add to Collection

Article Hematology

Long-term Outcomes in Patients With Multiple Myeloma A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)

Silvia G. R. Verelst et al.

HEMASPHERE (2018)

Add to Collection

Article Oncology

Trends in overall survival and costs of multiple myeloma, 2000-2014

R. Fonseca et al.

LEUKEMIA (2017)

Add to Collection

Article Oncology

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Juan-Jose Lahuerta et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Health Care Sciences & Services

Health care use and costs at the end of life: a comparison of elderly Australian decedents with and without a cancer history

Rebecca Reeve et al.

BMC PALLIATIVE CARE (2017)

Add to Collection

Article Education, Scientific Disciplines

Management of multiple myeloma in the newly diagnosed patient

Maria-Victoria Mateosi et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)

Add to Collection

Article Hematology

Recognition of early mortality in multiple myeloma by a prediction matrix

Howard Terebelo et al.

AMERICAN JOURNAL OF HEMATOLOGY (2017)

Add to Collection

Review Health Care Sciences & Services

Does facilitated Advance Care Planning reduce the costs of care near the end of life? Systematic review and ethical considerations

Corinna Klingler et al.

PALLIATIVE MEDICINE (2016)

Add to Collection

Article Oncology

Phase-specific and lifetime costs of cancer care in Ontario, Canada

Claire de Oliveira et al.

BMC CANCER (2016)

Add to Collection

Article Hematology

Multiple myeloma: patient outcomes in real-world practice

Kwee Yong et al.

BRITISH JOURNAL OF HAEMATOLOGY (2016)

Add to Collection

Article Oncology

Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study

Karin Jordan et al.

SUPPORTIVE CARE IN CANCER (2014)

Add to Collection

Article Oncology

Health Care Costs for Patients With Cancer at the End of Life

Benjamin Chastek et al.

JOURNAL OF ONCOLOGY PRACTICE (2012)

Add to Collection

Article Economics

EXPLORING THE INFLUENCE OF PROXIMITY TO DEATH ON DISEASE-SPECIFIC HOSPITAL EXPENDITURES: A CARPACCIO OF RED HERRINGS

Albert Wong et al.

HEALTH ECONOMICS (2011)

Add to Collection

Article Hematology

Improved survival in multiple myeloma and the impact of novel therapies

Shaji K. Kumar et al.

BLOOD (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.